Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis for BSX:

Technical Analysis BSX is showing strong bullish momentum with the stock trading at $98.66 as of the last close. The RSI of 75.27 indicates slightly overbought conditions, while the MACD at 2.11 confirms the positive trend. The stock is trading well above its 20-day moving average of $92.29, suggesting sustained upward momentum.

Recent Developments A significant development is Johnson & Johnson's pause of their Varipulse catheter launch due to safety concerns, which is highly positive for BSX's competitive position. Deutsche Bank recently upgraded BSX to Buy with a $108 price target, citing this development as removing a major overhang for 2025.

Analyst Consensus The stock maintains a strong "Buy" rating from analysts, with 23 out of 27 analysts recommending a "Strong Buy". The average price target is $100.92, suggesting a potential upside of 10.5% from current levels.

Conclusion BSX appears well-positioned for continued growth given:

• Removal of competitive pressure from J&J's Varipulse
• Strong analyst support and recent upgrades
• Positive technical indicators despite slightly overbought conditions

The stock is a buy at current levels, with potential near-term resistance around the $100 level based on Fibonacci analysis.

Based on the provided data and market analysis, here is the price prediction for BSX stock in 2025:

Technical Analysis Boston Scientific (BSX) shows strong upward momentum, reaching $98.66 as of January 17, 2025, with a clear bullish trend supported by increasing trading volumes. The stock has demonstrated consistent growth, rising from the $60s range in early 2024 to current levels near $100.

Price Target Analysis BSX is expected to reach $110-115 by end of 2025, representing a 10-15% upside from current levels, driven by:

1. Strong market position in medical devices sector, particularly in cardiology and electrophysiology

2. Continued momentum in key growth drivers including Farapulse and Watchman product lines

3. Multiple analyst upgrades with price targets in $100-110 range, including Deutsche Bank's recent upgrade to Buy with $108 target

Growth Catalysts

• Expanding product portfolio through strategic acquisitions
• Strong execution of core growth strategies
• Gaining market share in Pain and Brain franchises
• Momentum in Electrophysiology segment

The stock's valuation metrics suggest room for further upside despite the strong run-up, with forward P/E of 36.5x supported by projected 20% earnings growth.

The S1 support level for BSX Stock is $94.49 ,The R1 resistant level for BSX Stock is $101.32.

As of the end of day on 2025-01-24, the price of BSX Stock was $101.82.

The target price for BSX Stock according to analyst rating is 101.83, with the highest price target at 110.00 and the lowest at 86.00. Analysts have a Strong Buy rating on BSX Stock overall.

The market cap of BSX is $150.2B.

Based on the provided data, I'll analyze whether BSX is overvalued through multiple valuation metrics and recent analyst perspectives.

Valuation Analysis: BSX's current valuation metrics show elevated levels compared to historical averages:

• P/E ratio: 69.23 (Q3 2024)
• EV/EBITDA: 29.35 (Q3 2024)
• P/S ratio: 7.81 (Q3 2024)
• P/B ratio: 5.96 (Q3 2024)

Growth & Profitability: The company demonstrates solid growth with improving margins:

• Revenue growth: 9.1% YoY (Q3 2024)
• Gross margin: 64.15% (Q3 2024)
• Net margin: 11.12% (Q3 2024)
• ROE: 9.06% (Q3 2024)

Analyst Consensus: Recent analyst actions strongly support BSX's valuation:

• 23 Strong Buy ratings
• 1 Moderate Buy
• 3 Hold ratings
• Average price target: $100.92, implying 10.5% upside

BSX is currently trading at premium multiples, but the valuation appears justified given strong execution in core growth strategies, successful product launches, and expanding market opportunities. The company's diverse portfolio and new launches continue driving operational sales growth, particularly in MedSurg and Structural Heart lines.

The recent pause of Johnson & Johnson's Varipulse has strengthened BSX's competitive position in the medical device market, providing additional upside potential for the stock.

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

Based on the provided data and market analysis, here is the price prediction for Boston Scientific (BSX) stock in 2030:

BSX stock is projected to reach $165-175 by 2030, representing a 65-75% upside from current levels around $99, driven by continued market leadership in medical devices and strong execution of growth strategies. The company's expanding product portfolio, particularly in high-growth segments like electrophysiology and structural heart, combined with its robust pipeline of innovative medical technologies, positions it well for sustained growth. Recent strategic moves like the successful integration of acquisitions and focus on operational efficiency support this bullish long-term outlook.

BSX has a total of 48000 employees.